€66m Life Sciences Fund focused on Germa...Venture Capitalist Biogeneration Ventures has exceeded the target size of its life sciences fund BGV III through investments from the European Investment Banks InnovFin Equity Facility and the Dutch … more ➔
CHMP recommends several biologicsThe European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has recommended two antivirals, one biosimilar and two cancer meds for approval at its June meeting. more ➔
Roches lampalizumab halts geographic atr...A publication in Science Translational Medicine shows that Roche has a rising star in the 15 million patient market of age-related macular degeneration (AMD). In a Phase II trial, US and German researchers … more ➔
Epigenetic drugs set to boost immunoncolog... German oncologists have unveiled that market-approved inhibitors of DNA methyltransferases (DMNTi) and histone deacetylases (HDACi) act through expression of cancer neoantigens. They already have a … more ➔
AMD: Novartis challenges RegeneronFollowing shrinking sales for its wet AMD drug Lucentis, Novartis is back with convincing Phase III results of its anti-VEGF-A singe chain antibody fragment brolucizumab. In two pivotal studies the drug … more ➔
Evotec invests in Facio Therapies Evotec and co-investors support Dutch Facio Therapies BV with €4.8m to push development of Dux4 inhibitors to treat facioscapulohumeral dystrophy (FSHD), one of the most common forms of muscular dystrophy. more ➔
Delay in MAA for Asit Biotechs BTT009 Belgian Asit Biotech S.A. (formerly Biotech Tools) has announced that its grass pollen allergic rhinitis immunotherapy gp-ASIT+ did reach the primary efficacy endpoint in a Phase III trial but needs … more ➔
J&J completes acquisition of ActelionAfter todays completion of the acquisition of Actelion Ltd by J&J for US$30bn in cash, equivalent to US$280 per share, through the US companys Swiss subsidiary, Janssen Holding GmbH, Actelion … more ➔
Boehringer Ingelheims Humira biosimilar...Boehringer Ingelheim has presented detailed pivotal double-blinded Phase III data, which prove comparability of its biosimilar candidate BI695501 to Humira in patients with moderate to severe Rheumatoid … more ➔
Medicxi launches €267m fundNovartis and Alphabet/Google asset Verily Life Sciences LLC has co-invested into the late stage fund designed to finance programmes with up to €25m post clinical proof of concept. more ➔
